Aspirin blocks formation of metastatic intravascular niches by inhibiting platelet-derived COX-1/thromboxane A2
Serena Lucotti,Camilla Cerutti,Magali Soyer,Ana M. Gil-Bernabé,Ana L. Gomes,Philip D. Allen,Sean Smart,Bostjan Markelc,Karla Watson,Paul C. Armstrong,Jane A. Mitchell,Timothy D. Warner,Anne J. Ridley,Ruth J. Muschel
DOI: https://doi.org/10.1172/JCI121985
IF: 19.456
2019-10-07
Journal of Clinical Investigation
Abstract:Prostanoids are a family of bioactive lipids comprising prostaglandins (e.g., PGD 2 , PGE 2 , PGF 2a ), thromboxane A 2 (TXA 2 ), and prostacyclin (PGI 2 ). The rate-limiting step of prostanoid biosynthesis is catalyzed by cyclooxygenase (COX), an enzyme with 2 isoforms, COX-1 and COX-2. Both COX-1 and COX-2 have virtually identical enzymatic activity, mediating the conversion of arachidonic acid into PGG 2 and then into PGH 2 , the common precursor of all prostanoids ( 1 ). However, the spectrum of prostanoids synthesized by each isoform differs in vivo as a result of distinct expression patterns and functional coupling to prostanoid synthases in different cell types ( 2 ). For example, COX-2 is induced in endothelial cells and macrophages during inflammation and wound healing and couples with PGE 2 synthase in those cells to produce proinflammatory PGE 2 ( 2 , 3 ). In contrast, COX-1 is constitutively expressed. In platelets COX-1 couples with TXA 2 synthase (TXAS) to generate prothrombotic TXA 2 upon procoagulant stimuli (e.g., collagen, thrombin, and adenosine diphosphate [ADP]) ( 4 – 6 ). Because of the differential expression of prostanoid synthases and COX-1 and COX-2, the activity of the 2 isoforms is rarely redundant. The importance of COX and prostanoid pathways in metastasis is apparent from reports showing that their inhibition greatly curtails metastasis. NSAIDs, including aspirin, that inhibit both COX-1 and COX-2 generally reduce metastasis in clinical studies and murine models ( 7 – 9 ). In some reports specific COX-2 inhibition blocks metastasis ( 10 , 11 ), but not in others ( 12 ). Looking at the downstream prostanoids, inhibition of TXA 2 or of PGE 2 synthesis also reduces metastasis in animal models, while PGI 2 has been reported to inhibit metastasis ( 11 – 18 ), with some exceptions ( 12 , 19 ). These reports raise the question of whether some prostanoids might be suitable targets for metastasis prevention or therapy. The possibility of using COX or prostanoid synthesis inhibition as a preventive strategy for metastasis has been highlighted by both clinical and experimental studies. Aspirin is given clinically in a variety of doses to reduce cardiovascular events or inflammation. Because of its unique combination of irreversible inhibition of COX enzymes and short circulating half-life, low-dose aspirin preferentially inhibits COX-1 in platelets, reducing the production of prothrombotic TXA 2 and other prostanoids ( 20 ). Thus, low-dose aspirin is given for prophylaxis of myocardial infarction and stroke. Higher doses of aspirin inhibit both COX isoforms in other tissues ( 21 ). In particular, the reduction of COX-2–derived PGE 2 exerts antiinflammatory effects. Case-control studies and meta-analysis of randomized controlled trials have shown that aspirin given for these unrelated purposes reduces metastatic cancer ( 22 , 23 ). This effect was significant over a range of primary tumor types, with a more prominent effect on adenocarcinomas ( 23 ). While aspirin also reduces metastasis in murine models ( 8 , 11 , 24 , 25 ), it is not generally established whether the reduction of metastasis can be attributed to inhibition of COX-1 or COX-2. During hematogenous metastasis, tumor cells have adapted to co-opt diverse cell types, including platelets, endothelial cells, and immune cells, to survive the hostile environment of the blood circulation ( 26 ). In particular, cancer cells engage platelets to form small aggregates or clots on their surface through expression of tissue factor (TF) ( 27 ) or P-selectin ligands ( 28 , 29 ). Platelet aggregation and activation itself supports tumor cell survival in the circulation, either directly or through recruitment of myeloid cells, and can initiate cancer cell spreading on the surface of the blood vessel and transendothelial migration ( 27 , 29 – <a -Abstract Truncated-
medicine, research & experimental